The HbA1c and blood glucose response to pioglitazone in combination with another oral antidiabetic agent in patients with type 2 diabetes

2000 ◽  
Vol 50 ◽  
pp. 58 ◽  
Author(s):  
Renee Lebrizzi ◽  
John Egan
Keyword(s):  
Type 2 Diabetes ◽  
Blood Glucose ◽  
Antidiabetic Agent ◽  
Oral Antidiabetic Agent ◽  
Glucose Response ◽  
Blood Glucose Response ◽  
Oral Antidiabetic

scholarly journals Effects of a 12-week moderate-intensity exercise training on blood glucose response in patients with type 2 diabetes

Medicine ◽  
2019 ◽  
Vol 98 (36) ◽  
pp. e16860 ◽  
Author(s):  
Shang-Lin Chiang ◽  
Margaret McLean Heitkemper ◽  
Yi-Jen Hung ◽  
Wen-Chii Tzeng ◽  
Meei-Shyuan Lee ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Blood Glucose ◽  
Exercise Training ◽  
Moderate Intensity ◽  
Moderate Intensity Exercise ◽  
Glucose Response ◽  
Blood Glucose Response

scholarly journals Characteristics of some wheat-based foods of the Italian diet in relation to their influence on postprandial glucose metabolism in patients with type 2 diabetes

2001 ◽  
Vol 85 (1) ◽  
pp. 33-40 ◽  
Author(s):  
R. Giacco ◽  
F. Brighenti ◽  
M. Parillo ◽  
M. Capuano ◽  
A. V. Ciardullo ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Blood Glucose ◽  
Postprandial Glucose ◽  
Postprandial Blood Glucose ◽  
Diabetic Patients ◽  
White Bread ◽  
Glucose Response ◽  
Blood Glucose Response ◽  
Starchy Foods

The present study was aimed at evaluating in patients with type 2 diabetes: (1) the glycaemic response to four starchy foods based on wheat, typical of the Italian diet; (2) the importance of some food characteristics in relation to their effects on postprandial glucose response. Seventeen patients with type 2 diabetes (eleven men and six women) participated in the study. All patients consumed, in random order and on alternate days, 50 g available carbohydrate provided by 90 g white bread and, according to a randomised procedure, an equivalent amount of carbohydrate provided by one (n 8) or two (n 9) of three other different test foods (g): pizza 85, potato dumplings 165, hard toasted bread 60. Foods had a similar nutrient composition. Plasma glucose response, measured for 180 min, was significantly lower after the potato dumplings than after white bread at 90 (P<0·05), 120 (P<0·01) and 150 (P<0·05) min. No difference was observed in postprandial plasma insulin response after the various test foods. The percentage of starch hydrolysed after 5 h in vitro hydrolysis with α-amylase was about 30 % lower for potato dumplings than for the other foods. However, no differences in the resistant starch content, the rate of diffusion of simple sugars added to a dialysis tube containing the food, and the viscosity of digesta were observed among the test foods. Scanning electron microscopy of potato dumplings showed a compact structure compatible with impaired accessibility of starch to digestive enzymes. In conclusion, carbohydrate-rich foods typical of the Italian diet which are often consumed as an alternative to pasta dishes are not equivalent in terms of metabolic impact in diabetic patients. Due to their low blood glucose response, potato dumplings represent a valid alternative to other starchy foods in the diabetic diet. Food structure plays an important role in determining starch accessibility to digestion, thus influencing the postprandial blood glucose response.

scholarly journals An increase in dietary protein improves the blood glucose response in persons with type 2 diabetes

2003 ◽  
Vol 78 (4) ◽  
pp. 734-741 ◽  
Author(s):  
Mary C Gannon ◽  
Frank Q Nuttall ◽  
Asad Saeed ◽  
Kelly Jordan ◽  
Heidi Hoover
Keyword(s):  
Type 2 Diabetes ◽  
Blood Glucose ◽  
Dietary Protein ◽  
Glucose Response ◽  
Blood Glucose Response

Proposal for the administration of metformin in patients with chronic kidney disease

2012 ◽  
Vol 153 (39) ◽  
pp. 1527-1535 ◽  
Author(s):  
Zoltán Balogh ◽  
János Mátyus
Keyword(s):  
Lactic Acidosis ◽  
Chronic Renal Disease ◽  
Antidiabetic Agent ◽  
First Line ◽  
Oral Antidiabetic Agent ◽  
Oral Antidiabetic ◽  
Cardiovascular Morbidity And Mortality ◽  
Glomerular Filtrate ◽  
Life Threatening

Metformin is the first-line, widely used oral antidiabetic agent for the management of type 2 diabetes. There is increasing evidence that metformin use results in a reduction in cardiovascular morbidity and mortality, and might have anticancer activity. An extremely rare, but potentially life-threatening adverse effect of metformin is lactic acidosis, therefore, its use is traditionally contraindicated if the glomerular filtrate rate is below 60 mL/min. However, lactic acidosis is always associated with acute events, such as hypovolemia, acute cardiorespiratory illness, severe sepsis and acute renal or hepatic failure. Furthermore, administration of insulins and conventional antihyperglycemic agents increases the risk of severe hypoglycemic events when renal function is reduced. Therefore, the magnitude of the benefit of metformin use would outweigh potential risk of lactic acidosis in moderate chronic renal disease. After reviewing the literature, the authors give a proposal for the administration of metformin, according to the calculated glomerular filtrate rate. Orv.Hetil., 2012, 153, 1527–1535.

Prolonged Effect of Troglitazone (CS-045) on Xenograft Survival of Hybrid Artificial Pancreas

1997 ◽  
Vol 6 (5) ◽  
pp. 547-550 ◽  
Author(s):  
Yoshiyuki Kawakami ◽  
Kazutomo Inoue ◽  
Tein Tun ◽  
Hiroyuki Hayashi ◽  
Hiroshi Setoyama ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Treated Group ◽  
Control Group ◽  
Antidiabetic Agent ◽  
Bioartificial Pancreas ◽  
Oral Antidiabetic Agent ◽  
Rat Islets ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Oral Antidiabetic

Troglitazone (CS-045), a thiazolidinedione derivative, is a new oral antidiabetic agent that enhances insulin sensitivity and improves insulin responsiveness. In this study we examined the effects of CS-045 on the survival of xenografted bioartificial pancreas. Isolated rat islets were microencapsulated with three-layer agarose microcapsules (polybrene, carboxymethyl cellulose, and an agarose-polystyrene sulfonic acid mixture). Diabetes was induced by intraperitoneal injection of streptozotocin 220 mg/kg. Recipient diabetic mice were separated into two groups. In the CS-045 treated group, the recipient mice were given feed mixed with CS-045 (0.2% w/w) starting from 1 wk before transplantation up to graft failure. The mice in the control group had feed without CS-045. Three hundred microencapsulated rat islets were xenotransplanted into the intraperitoneal cavity of each recipient mouse in both groups. One month after xenotransplantation, IVGTT was performed for all recipients. Xenotransplantation of 300 rat islets in microcapsules decreased the nonfasting blood glucose levels of both groups within 2 days. In the CS-045-treated group (n = 3), the normoglycemic period lasted for more than 1 mo without administration of immunosuppressive drugs (45 ± 4.3 days). However, in the control group (n = 4), the blood glucose levels of all recipients were already elevated on day 4. In the IVGTT study, the glucose assimilation was markedly and significantly better in the CS-045-treated group than in the control group (K = 1.7 ± 0.1 vs. 0.7 ± 0.28 respectively, p <0.01). This study demonstrates that a newly developed oral antidiabetic agent, CS-045 could favorably ameliorate the diabetic state of the recipients xenotransplanted with the bioartificial pancreas, leading to an improved glucose tolerance and longer xenograft survival.

Sign in / Sign up

Export Citation Format

Share Document